Section H Update for Hospital Pharmaceuticals
Effective 1 March 2017
Cumulative for December 2016, January, February and March 2017
Contents

Summary of decisions effective 1 March 2017 ..................................................... 3
Section H changes to Part II ................................................................................. 4
Index ....................................................................................................................... 31
• Alprazolam tab 1 mg, 250 mcg and 500 mcg – to be delisted 1 September 2017
• Dosulepin [dothiepin] hydrochloride (Dopress) tab 75 mg and cap 25 mg – chemical name amended
• Glucose with potassium chloride and sodium chloride (Baxter) inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45% 1,000 ml bag – new listing
• Glucose with potassium chloride and sodium chloride (Baxter) inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9% 1,000 ml bag – new listing
• Interferon beta-1-alpha (Avonex) inj 6 million iu vial – to be delisted 1 June 2017
• Lidocaine [lignocaine] hydrochloride (Lidocaine-Claris) inj 1% and 2%, 20 ml vial – new listing
• Mesalazine (Asacol) tab 800 mg – price decrease
• Methyldopa (Prodopa) tab 125 mg and 250 mg – to be delisted 1 May 2017
• Ondansetron (Apo-Ondansetron) tab 4 mg and 8 mg – new listing and addition of HSS
• Ondansetron (Onrex) tab 4 mg and 8 mg – to be delisted 1 May 2017
• Peptide-based oral feed (Alitraq) powder 15.8 g protein, 49.5 carbohydrate and 4.65 g fat per 76 g sachet – to be delisted 1 September 2017
• Rizatriptan (Rizamelt) tab orodispersible 10 mg – 12 tab pack to be delisted 1 May 2017
• Sodium chloride irrigation soln 0.9%, 30 ml ampoule – amended unit of measure
• Sodium thiosulfate inj 250 mg per ml, 50 ml vial – new listing
Section H changes to Part II
Effective 1 March 2017

ALIMENTARY TRACT AND METABOLISM

14  MESALAZINE (I. price)
    Tab 800 mg ................................................................. 85.50  90  Asacol

BLOOD AND BLOOD FORMING ORGANS

38  GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE (new listing)
    Inj 5% glucose with potassium chloride 20 mmol/l and
    sodium chloride 0.9%, bag ........................................... 12.50  1,000 ml  Baxter
    Inj 5% glucose with potassium chloride 20 mmol/l and
    sodium chloride 0.45%, bag ........................................... 8.29  1,000 ml  Baxter

CARDIOVASCULAR SYSTEM

46  METHYLDOPA (delisting)
    Tab 125 mg ................................................................. 14.25  100  Prodopa
    Tab 250 mg ................................................................. 15.10  100  Prodopa
    Note – Prodopa tab 125 mg and 250 mg to be delisted from 1 May 2017.

NERVOUS SYSTEM

111  LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (new listing)
    Inj 1%, 20 ml vial............................................................. 12.00  5  Lidocaine-Claris
    Inj 2%, 20 ml vial............................................................. 12.00  5  Lidocaine-Claris

115  DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE (chemical name amended)
    Tab 75 mg ................................................................. 11.19  100  Dopress
    Cap 25 mg ................................................................. 6.45  100  Dopress

121  RIZATRIPTAN (delisting)
    Tab orodispersible 10 mg – 1% DV Sep-14 to 2017 .......... 3.24  12  Rizamelt
    Note – Rizamelt tab orodispersible 10 mg, 12 tab pack, to be delisted from 1 May 2017. The 30 tablet pack remains listed.

123  ONDANSETRON (brand change)
    Tab 4 mg – 1% DV May-17 to 2019 ......................... 3.36  50  Apo-Ondansetron
    Tab 8 mg – 1% DV May-17 to 2019 ......................... 4.77  50  Apo-Ondansetron
    Note – Onrex tab 4 mg and 8 mg to be delisted from 1 May 2017.

127  ALPRAZOLAM – Restricted: For continuation only (delisting)
    ➔ Tab 1 mg
    ➔ Tab 250 mcg
    ➔ Tab 500 mcg
    Note – Alprazolam tab 250 mcg, 500 mcg and 1 mg to be delisted from 1 September 2017.
Changes to Section H Part II – effective 1 March 2017 (continued)

128 INTERFERON BETA-1-ALPHA (delisting)
Inj 6 million iu vial .......................................................... 1,170.00 4 Avonex
Note – Avonex inj 6 million iu per ml, 1 ml vial to be delisted from 1 June 2017. Avonex Pen pen injector and Avonex syringe will remain listed.

VARIOUS

195 SODIUM THIOSULFATE (new listing)
Inj 250 mg per ml, 50 ml vial

201 SODIUM CHLORIDE (amended unit of measure)
Irrigation soln 0.9%, 30 ml ampoule ........................................ 19.50 30 inj Pfizer
Note – This pack is supplied in a 30 ampoule pack, not in single 30 ml ampoules.

SPECIAL FOODS

212 PEPTIDE-BASED ORAL FEED
► Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet .......................................................... 7.50 76 g Alitraq
Note – Alitraq powder 76 g sachets to be delisted from 1 September 2017.

Effective 1 February 2017

ALIMENTARY TRACT AND METABOLISM

18 METFORMIN HYDROCHLORIDE (new listing)
Tab immediate-release 850 mg.............................................. 7.82 500 Apotex

18 METFORMIN HYDROCHLORIDE (HSS suspended)
Tab immediate-release 850 mg
– 1% DV Dec-15 to 2016 ........................................ 7.82 500 Metformin Mylan

BLOOD AND BLOOD FORMING ORGANS

36 FILGRASTIM (pack size change)
► Inj 300 mcg in 1 ml vial .................................................. 520.00 4 Neupogen
Note – Neupogen inj 300 mcg in 1 ml vial, 5 inj pack, to be delisted from 1 February 2017.

CARDIOVASCULAR SYSTEM

42 TERAZOSIN (brand change)
Tab 2 mg – 1% DV Apr-17 to 2019 ........................................ 7.50 500 Apo-Terazosin
Note – Arrow terazosin tab 2 mg to be delisted from 1 April 2017.

INFECTIONS

74 GENTAMICIN SULPHATE (delisting)
Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018 ...... 30.00 50 Pfizer
Note – Pfizer gentamicin sulphate inj 40 mg per ml, 2 ml ampoule, 50 inj pack, to be delisted from 1 August 2017. The 10 inj pack remains listed.
Changes to Section H Part II – effective 1 February 2017 (continued)

NERVOUS SYSTEM

113 CODEINE PHOSPHATE (1 price and addition of HSS)

<table>
<thead>
<tr>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

Tab 15 mg – 1% DV Apr-17 to 2019 ........................................ 5.75 100 PSM
Tab 30 mg – 1% DV Apr-17 to 2019 ........................................ 6.80 100 PSM
Tab 60 mg – 1% DV Apr-17 to 2019 ........................................ 13.50 100 PSM

117 PAROXETINE HYDROCHLORIDE (amended chemical name and brand change)

<table>
<thead>
<tr>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

Tab 20 mg – 1% DV Apr-17 to 2019 ........................................ 4.02 90 Apo-Paroxetine

Note – Loxamine tab 20 mg to be delisted from 1 April 2017.

121 SUMATRIPTAN (brand change)

<table>
<thead>
<tr>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

Inj 12 mg per ml, 0.5 ml prefilled pen ..................................... 42.67 2 Clustran

Note – Arrow-Sumatriptan inj 12 mg per ml, 0.5 ml cartridge to be delisted from 1 July 2017.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137 CYTARABINE (delisting)

<table>
<thead>
<tr>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

Inj 20 mg per ml, 25 ml vial .................................................. 18.15 1 Pfizer

Note – Pfizer cytarabine inj 20 mg per ml, 25 ml vial to be delisted from 1 February 2017.

155 ADALIMUMAB (delisting)

<table>
<thead>
<tr>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

⇒ Inj 10 mg per 0.2 ml prefilled syringe .................................. 1,599.96 2 Humira

Note – Humira inj 10 mg per 0.2 ml prefilled syringe to be delisted from 1 August 2017.

175 TOCILIZUMAB (amended restriction – amended criteria shown only)

<table>
<thead>
<tr>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

⇒ Inj 20 mg per ml, 4 ml vial ................................................ 220.00 1 Actemra
⇒ Inj 20 mg per ml, 10 ml vial .............................................. 550.00 1 Actemra
⇒ Inj 20 mg per ml, 20 ml vial .............................................. 1,100.00 1 Actemra

Restricted

Initiation — cytokine release syndrome
Paediatric haematologist, paediatric oncologist

Therapy limited to 3 doses
All of the following:
1. The patient is enrolled in the Children’s Oncology Group AALL1331 trial; and
2. The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
3. Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

SPECIAL FOODS

219 ORAL FEED (delisting)

<table>
<thead>
<tr>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

⇒ Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can .................................................. 26.00 850 g Ensure (Chocolate)
Ensure (Vanilla)

Note – Ensure powder 850 g chocolate (Pharmacode 2453991) and vanilla (Pharmacode 2447223) to be delisted from 1 August 2017.
Changes to Section H Part II – effective 1 February 2017 (continued)

VACCINES

225  HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] (amended restriction)
     ➔ Inj 120 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017 .......... 0.00 10  Gardasil
     Restricted
     Initiation — people aged 9 to 26 years
     Therapy limited to 3 doses
     Any of the following:
     1. Up to three doses for people aged 9 to 26 years inclusive
     2. Patients aged under 26 years old with confirmed HIV infection; or
     3. For use in transplant (including stem cell) patients; or
     Initiation — post chemotherapy
     Therapy limited to 4 doses
     4. Up to 4 doses

225  INFLUENZA VACCINE (addition of HSS)
     ➔ Inj 45 mcg in 0.5 ml syringe
     – 0% DV Feb-17 to 31 Dec 2019 ............................... 90.00 10  Influvac

225  INFLUENZA VACCINE (delisting)
     ➔ Inj 45 mcg in 0.5 ml syringe .............................. 90.00 10  Fluarix
     Note – Fluarix inj 45 mcg in 0.5 ml syringe to be delisted from 1 February 2017.

Effective 16 January 2017

BLOOD AND BLOOD FORMING ORGANS

43  PEGFILGRASTIM (Pharmacode change)
     ➔ Inj 6 mg per 0.6 ml syringe ................................. 1,080.00 1  Neulastim
     Note – Neulastim inj 6 mg per 0.6 ml syringe (Pharmacode 2265478) to be delisted from 1 September 2017.

Effective 1 January 2017

ALIMENTARY TRACT AND METABOLISM

22  CALCIUM CARBONATE (delisting)
     Tab eff 1.75 g (1 g elemental) .............................. 6.21 30  Calsource
     Note – Calsource tab eff 1.75 g (1 g elemental), 30 tab pack, to be delisted from 1 July 2017. The 10 tab pack remains listed.

BLOOD AND BLOOD FORMING ORGANS

35  CLOPIDOGREL (4 price and addition of HSS)
     Tab 75 mg – 1% DV Mar-17 to 2019 ............................. 5.44 84  Arrow - Clopid
Changes to Section H Part II – effective 1 January 2017 (continued)

38 SODIUM CHLORIDE (brand change)
   Inj 0.9%, 5 ml ampoule – 1% DV Mar-17 to 2019.................... 7.00  50 InterPharma
   Inj 0.9%, 20 ml ampoule – 1% DV Mar-17 to 2019.................... 7.50  30 InterPharma
Note – Multichem sodium chloride inj 0.9%, 5 ml and 20 ml ampoules, and Pfizer sodium chloride inj 0.9%, 5 ml ampoule to be delisted from 1 March 2017.

38 SODIUM CHLORIDE (+ price and addition of HSS)
   Inj 0.9%, 10 ml ampoule – 1% DV Mar-17 to 2019.................... 6.33  50 Pfizer
Note – Multichem sodium chloride inj 0.9%, 10 ml ampoule to be delisted from 1 March 2017.

39 WATER (brand change)
   Inj 5 ml ampoule – 1% DV Mar-17 to 2019.................... 7.00  50 InterPharma
   Inj 10 ml ampoule – 1% DV Mar-17 to 2019.................... 6.63  50 Pfizer
   Inj 20 ml ampoule – 1% DV Mar-17 to 2019.................... 7.50  30 InterPharma
Note – Multichem water inj 5 ml, 10 ml and 20 ml ampoules to be delisted from 1 March 2017.

CARDIOVASCULAR SYSTEM

49 GLYCERYL TRINITRATE (delisting)
   Inj 1 mg per ml, 50 ml vial........................................ 86.60  10 Nitronal
Note – Nitronal inj 1 mg per ml, 50 ml vial to be delisted from 1 July 2017.

50 PHENYLEPHRINE HYDROCHLORIDE (delisting)
   Inj 10 mg per ml, 1 ml vial................................... 115.50  25 Neosynephrine HCL
Note – Neosynephrine HCL inj 10 mg per ml, 1 ml vial, Pharmacode 2120720, to be delisted from 1 January 2017.

50 PHENYLEPHRINE HYDROCHLORIDE (new listing)
   Inj 10 mg per ml, 1 ml ampoule.................................. 115.50  25 Neosynephrine HCL
Note – this is the listing of the ampoule with a new Pharmacode, 2341069.

HORMONE PREPARATIONS

66 OESTRADIOL (new listing)
   Patch 75 mcg per day – 1% DV Mar-17 to 2019.................... 7.91  8 Estradot

68 SOMATROPIN (amended restriction – amended criteria shown only)
   Inj 5 mg cartridge – 1% DV Jan-15 to 31 Dec 2017........... 109.50  1 Omnitrope
   Inj 10 mg cartridge – 1% DV Jan-15 to 31 Dec 2017......... 219.00  1 Omnitrope
   Inj 15 mg cartridge – 1% DV Jan-15 to 31 Dec 2017........... 328.50  1 Omnitrope
Restricted
Initiation — Prader-Willi syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
2 The patient’s height velocity is < 25th percentile for bone age adjusted for bone age/pubertal status if appropriate as calculated over 6 to 12 months using the standards of Tanner and Davies (1985) or pubertal status over 6 to 12 months; and
3 Either: continued...
3.1 The patient is under two years of age and height velocity has been assessed over a minimum six-month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity < 25th percentile); or

3.2 The patient is aged two years or older; and

2 The patient is aged six months or older; and

3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and

4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and

5 Either:

5.1 Both:

5.1.1 The patient is aged two years or older; and

5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months; or

5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

INFECTIONS

88 DIDANOSINE [DDI] (delisting)

→ Cap 125 mg
→ Cap 200 mg
→ Cap 250 mg
→ Cap 400 mg

Note – Didanosine [DDI] cap 125 mg, 200 mg, 250 mg and 400 mg to be delisted from 1 July 2017.

MUSCULOSKELETAL SYSTEM

100 RISERONATE SODIUM (4 price and addition of HSS)

Tab 35 mg – 1% DV Mar-17 to 2019 ........................................ 3.80 4 Risedronate Sandoz

103 ALLOPURINOL (HSS added)

Tab 100 mg – 1% DV Jan-17 to 2017 ................................. 15.11 1,000 Allopurinol-Apotex
Tab 300 mg – 1% DV Jan-17 to 2017 ................................. 15.91 500 Allopurinol-Apotex

103 ALLOPURINOL (HSS removed)

Tab 100 mg – 1% DV Mar-15 to 31 Dec 2016 .......................... 15.11 1,000 Apo-Allopurinol
Tab 300 mg – 1% DV Mar-15 to 31 Dec 2016 .......................... 15.91 500 Apo-Allopurinol

103 BENZBROMARONE (website address amended)

→ Tab 100 mg................................................................. 45.00 100 Benzbromaron AL 100

Restricted Initiation
Any specialist
All of the following:
1 Patient has been diagnosed with gout; and
2 Any of the following:
Changes to Section H Part II – effective 1 January 2017 (continued)

continued...

2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

2.3 Both:

2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and

2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or

2.4 All of the following:

2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and

2.4.2 Allopurinol is contraindicated; and

2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and

3 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/home/resources-2/


NERVOUS SYSTEM

115 TRAMADOL HYDROCHLORIDE (new listing)
   Oral soln 10 mg per ml

115 TRAMADOL HYDROCHLORIDE (delisting)
   Oral drops 100 mg per ml
   Note – Tramadol hydrochloride oral drops 100 mg per ml to be delisted from 1 July 2017.

117 DIAZEPAM (*price)
   Rectal tubes 5 mg ......................................................... 33.07  5  Stesolid
   Rectal tubes 10 mg ....................................................... 40.87  5  Stesolid

121 SUMATRIPTAN (delisting)
   Inj 12 mg per ml, 0.5 ml cartridge ..................................... 13.80  2  Arrow-Sumatriptan
   Note – Arrow-Sumatriptan inj 12 mg per ml, 0.5 ml cartridge to be delisted from 1 July 2017.

125 TRIFLUOPERAZINE HYDROCHLORIDE – Restricted: for continuation only (restriction added and delisting)
   ➔ Tab 1 mg
   ➔ Tab 2 mg
   ➔ Tab 5 mg
   Note: Trifluoperazine hydrochloride tab 1 mg, 2 mg and 5 mg to be delisted from 1 December 2017.

126 FLUPHENAZINE DECANOATE (new listing)
   ➔ Inj 25 mg per ml, 2 ml ampoule  e.g. Modecate

Restriction
(Brand) indicates a brand example only. It is not a contracted product.
## Changes to Section H Part II – effective 1 January 2017 (continued)

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Name</th>
<th>Price (ex man. Excl. GST)</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>132</td>
<td>BUPROPION HYDROCHLORIDE († price)</td>
<td>Tab modified-release 150 mg</td>
<td>11.00</td>
<td>30</td>
</tr>
<tr>
<td>132</td>
<td>DISULFIRAM († price)</td>
<td>Tab 200 mg</td>
<td>44.30</td>
<td>100</td>
</tr>
<tr>
<td>133</td>
<td>NALTREXONE HYDROCHLORIDE († price)</td>
<td>Tab 50 mg</td>
<td>131.00</td>
<td>30</td>
</tr>
</tbody>
</table>

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Name</th>
<th>Price (ex man. Excl. GST)</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>141</td>
<td>ERLOTINIB († price and HSS removed)</td>
<td>Tab 100 mg – 1% DV Jun-15 to 31 Dec 2016</td>
<td>764.00</td>
<td>30</td>
</tr>
<tr>
<td>141</td>
<td>ERLOTINIB († price and HSS removed)</td>
<td>Tab 150 mg – 1% DV Jun-15 to 31 Dec 2016</td>
<td>1,146.00</td>
<td>30</td>
</tr>
<tr>
<td>149</td>
<td>ETANERCEPT (new Pharmacode listing)</td>
<td>Inj 50 mg autoinjector</td>
<td>1,599.96</td>
<td>4</td>
</tr>
</tbody>
</table>

Note – Enbrel inj 50 mg autoinjector (Pharmacode 2375729) to be delisted from 1 August 2017.

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Name</th>
<th>Price (ex man. Excl. GST)</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>166</td>
<td>OBINUTUZUMAB (new listing)</td>
<td>Inj 25 mg per ml, 40 ml vial</td>
<td>5,910.00</td>
<td>1</td>
</tr>
</tbody>
</table>

Restricted
Initiation
Haematologist
Limited to 6 months treatment
All of the following:
1. The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
2. The patient is obinutuzumab treatment naive; and
3. The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance <70mL/min); and
4. Patient has adequate neutrophil and platelet counts (≥1.5 x 10^9/L and platelets ≥75 x 10^9/L) unless the cytopenias are a consequence of marrow infiltration by CLL; and
5. Patient has good performance status; and
6. Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to <2.

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Name</th>
<th>Price (ex man. Excl. GST)</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>167</td>
<td>PERTUZUMAB (new listing)</td>
<td>Inj 30 mg per ml, 14 ml vial</td>
<td>3,927.00</td>
<td>1</td>
</tr>
</tbody>
</table>

Restricted
Initiation
Re-assessment required after 12 months
All of the following:
1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Either: 

Note: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to <2.
Changes to Section H Part II – effective 1 January 2017 (continued)

2.1 Patient is chemotherapy treatment naïve; or
2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
3 The patient has good performance status (ECOG grade 0-1); and
4 Pertuzumab to be administered in combination with trastuzumab; and
5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
6 Pertuzumab to be discontinued at disease progression.

Continuation
Re-assessment required after 12 months
Both:
1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

167 RITUXIMAB (amended restriction – amended criteria shown only)

- Inj 10 mg per ml, 10 ml vial.................................1,075.50 2 Mabthera
- Inj 10 mg per ml, 50 ml vial.................................2,688.30 1 Mabthera

Restricted
Initiation — indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 9 months
Either:
1 Both:
   1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
   1.2 To be used for a maximum of 6 treatment cycles; or
2 Both:
   2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: ‘Indolent, low-grade lymphomas’ includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ‘Hairy cell leukaemia’ also includes hairy cell leukaemia variant.

Continuation — indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 9 months
All of the following:
1 The patient has had a rituximab treatment-free interval of 12 months or more; and
2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
3 To be used for no more than 6 treatment cycles.

Note: ‘Indolent, low-grade lymphomas’ includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ‘Hairy cell leukaemia’ also includes hairy cell leukaemia variant.

Continuation — Chronic lymphocytic leukaemia

Re-assessment required after 12 months
All of the following:
1 The patient’s disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
2 The patient has had a rituximab treatment–free interval of 36 months or more; and

continued...
Changes to Section H Part II – effective 1 January 2017 (continued)

3 The patient does not have chromosome 17p deletion CLL; and

4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration); and

5 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation — ANCA associated vasculitis

Re-assessment required after 4 weeks

All of the following:

1 Patient has been diagnosed with ANCA associated vasculitis*; and

2 Either:

   2.1 Patient does not have MPO-ANCA positive vasculitis*; or

   2.2 Mycophenolate mofetil has not been effective in those patients who have MPO-ANCA positive vasculitis*; and

23 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and

34 Any of the following:

   34.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve complete absence significant improvement of disease after at least 3 months; or

   34.2 Patient has previously had a cumulative dose of cyclophosphamide >15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose >15 g; or

   34.3 Cyclophosphamide and methotrexate are contraindicated; or

   34.4 Patient is a female of child-bearing potential; or

   34.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are Unapproved Indications.

175 TOCILIZUMAB (amended restriction – amended criteria shown only)

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ex man. Excl. GST) $</td>
<td>Per Manufacturer</td>
</tr>
<tr>
<td>220.00</td>
<td>1 Actemra</td>
</tr>
<tr>
<td>550.00</td>
<td>1 Actemra</td>
</tr>
<tr>
<td>1,100.00</td>
<td>1 Actemra</td>
</tr>
</tbody>
</table>

Restricted

Initiation — Rheumatoid Arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1 All of the following:

   1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and

   1.2 Either:

      1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or

      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and

   1.3 Either:

      1.3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or

      1.3.2 Both:

         1.3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and

continued...
Changes to Section H Part II – effective 1 January 2017 (continued)

1.3.2.1 Either:
   1.3.2.1.1 The patient has experienced intolerable side effects from rituximab; or
   1.3.2.1.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or

1.3 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and

1.4 Either:
   1.4.1 The patient has experienced intolerable side effects from rituximab; or
   1.4.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or

2 All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Tocilizumab is to be used as monotherapy; and
   2.3 Either:
      2.3.1 Treatment with methotrexate is contraindicated; or
      2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and

2.4 Either:
   2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or
   2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and

2.5 Either:
   2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
   2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.6 Either:
   2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation — polyarticular juvenile idiopathic arthritis

Rheumatologist
Re-assessment required after 4 months.

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or

2 All of the following:
   2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
   2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
   2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

continued...
Changes to Section H Part II – effective 1 January 2017 (continued)

2.5 Both:
   2.5.1 Either:
   2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
   2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

   2.5.2 Physician’s global assessment indicating severe disease.

Continuation — polyarticular juvenile idiopathic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician’s global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline.

Initiation — idiopathic multicentric Castleman’s disease

Haematologist or rheumatologist

Re-assessment required after 6 months

All of the following:
1 Patient has severe HHV-8 negative idiopathic multicentric Castleman’s disease; and
2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Continuation — idiopathic multicentric Castleman’s disease

Haematologist or rheumatologist

Re-assessment required after 12 months

The treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

177 TRASTUZUMAB (amended restriction – amended criteria shown only)

   ➔ Inj 150 mg vial.......................................................... 1,350.00 1 Herceptin
   ➔ Inj 440 mg vial.......................................................... 3,875.00 1 Herceptin

Initiation — metastatic breast cancer (trastuzumab-naive patients)

Limited to 12 months treatment

All of the following:
1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
      2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
      2.2.2 The cancer did not progress whilst on lapatinib; and
3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:  

continued...
Changes to Section H Part II – effective 1 January 2017 (continued)

3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and

5 Trastuzumab to be discontinued at disease progression.

Either:

1 All of the following:
   1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   1.2 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; and
   1.3 Trastuzumab not to be given in combination with lapatinib; and
   1.4 Trastuzumab to be discontinued at disease progression; or

2 All of the following:
   2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
   2.3 The cancer did not progress whilst on lapatinib; and
   2.4 Trastuzumab not to be given in combination with lapatinib; and
   2.5 Trastuzumab to be discontinued at disease progression.

Initiation — metastatic breast cancer (patients previously treated with trastuzumab)

Limited to 12 months treatment

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
      2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
      2.2.2 The cancer did not progress whilst on lapatinib; and

3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
      3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and

5 Trastuzumab to be discontinued at disease progression.

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and

3 Any of the following:
   3.1 All of the following:

continued...
Changes to Section H Part II – effective 1 January 2017 (continued)

3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
3.1.2 Trastuzumab not to be given in combination with lapatinib; and
3.1.3 Trastuzumab to be discontinued at disease progression; or

3.2 All of the following:
3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
3.2.2 The cancer did not progress whilst on lapatinib; and
3.2.3 Trastuzumab not to be given in combination with lapatinib; and
3.2.4 Trastuzumab to be discontinued at disease progression; or

3.3 All of the following:
3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
3.3.2 Trastuzumab not to be given in combination with lapatinib; and
3.3.3 Trastuzumab to be discontinued at disease progression.

RESPIRATORY SYSTEM AND ALLERGIES

PIRFENIDONE (new listing)

Cap 267 mg..........................................................3,645.00 270 Esbriet

Restricted
Initiation
Respiratory specialist
Re-assessment required after 12 months
All of the following:
1 Patient has been diagnosed with idiopathic pulmonary fibrosis as confirmed by histology, CT or biopsy; and
2 Forced vital capacity is between 50% and 80% predicted; and
3 Pirfenidone is to be discontinued at disease progression (See Notes).

Continuation
Respiratory specialist
Re-assessment required after 12 months
Both:
1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2 Pirfenidone is to be discontinued at disease progression (See Notes).

Notes: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

VARIOUS

IODISED OIL († price)

Inj 38% w/w (480 mg per ml), 10 ml ampoule .................230.00 1 Lipiodol Ultra Fluid

SPECIAL FOODS

PAEDIATRIC ORAL FEED († price)

Powder 14.9 g protein, 54.3 g carbohydrate and 24.7 g fat per 100 g, can...............................................................28.00 850 g Pediasure (Vanilla)
Changes to Section H Part II – effective 1 January 2017 (continued)

219 \( \text{ORAL FEED (t price)} \)

\[ \rightarrow \text{Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat} \]
\[ \text{per 100 g, can} \]
\[ \text{26.00 $26.00} \]
\[ \text{850 g} \]

Ensure (Chocolate)
Ensure (Vanilla)

\[ \rightarrow \text{Powder 16 g protein, 59.8 g carbohydrate and 14 g fat} \]
\[ \text{per 100 g, can} \]
\[ \text{26.00 $26.00} \]
\[ \text{850 g} \]

Ensure (Chocolate)
Ensure (Vanilla)

VACCINES

225 \( \text{HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] (new listing)} \)

\[ \rightarrow \text{Inj 270 mcg in 0.5 ml syringe – } 0\% \text{ DV Jul-17 to 2020 } \]
\[ \text{0.00 $0.00} \]
\[ \text{10} \]

Gardasil 9

Restricted
Initiation – children aged 14 years and under

*Therapy limited to 2 doses*

Children aged 14 years and under.

Initiation – other conditions

Either:

1. Up to 3 doses for people aged 15 to 26 years inclusive; or
2. Both:
   2.1 People aged 9 to 26 years inclusive; and
   2.2 Any of the following:
      2.2.1 Up to 3 doses for confirmed HIV infection; or
      2.2.2 Up to 3 doses for transplant (including stem cell) patients: or
      2.2.3 Up to 4 doses for Post chemotherapy.

225 \( \text{HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] (delisting)} \)

\[ \rightarrow \text{Inj 120 mcg in 0.5 ml syringe – } 1\% \text{ DV Jul-14 to 2017 } \]
\[ \text{0.00 $0.00} \]
\[ \text{10} \]

Gardasil

Note – Gardasil inj 120 mcg in 0.5 ml syringe to be delisted from 1 October 2017.
## Changes to Section H Part II – effective 1 December 2016

### ALIMENTARY TRACT AND METABOLISM

#### 20 ALGLUCOSIDASE ALFA

<table>
<thead>
<tr>
<th>Brand</th>
<th>Price (ex man. Excl. GST)</th>
<th>Per Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myozyme</td>
<td>1,142.60</td>
<td>1</td>
</tr>
</tbody>
</table>

Restricted

Initiation

Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
2. Any of the following:
   2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
   2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
   2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
   2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
3. Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
4. Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might reasonably be expected to compromise a response to ERT; and
5. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Continuation

Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
3. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
4. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
5. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
6. There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation.
7. There is no evidence of new or progressive cardiomyopathy.

#### 21 IDURSULFASE

<table>
<thead>
<tr>
<th>Brand</th>
<th>Price (ex man. Excl. GST)</th>
<th>Per Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elaprase</td>
<td>4,608.30</td>
<td>1</td>
</tr>
</tbody>
</table>

Restricted

Metabolic physician

Limited to 24 weeks treatment

All of the following:

1. The patient has been diagnosed with Hunter Syndrome (mucopolysaccharosis II); and
2. Either:

   - "continued..."
Changes to Section H Part II – effective 1 December 2016 (continued)

2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts or
2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and.
4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

<table>
<thead>
<tr>
<th>CARDIOVASCULAR SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>42 TERAZOSIN (brand change)</td>
</tr>
<tr>
<td>Note – Arrow terazosin tab 5 mg to be delisted from 1 February 2017.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DERMATOLOGICALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>56 HYDROCORTISONE (new listing)</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of less than or equal to 100 g.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HORMONE PREPARATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>66 PREDNISONE (delisting)</td>
</tr>
<tr>
<td>Note – Apo-Prednisone S29 tab 1 mg to be delisted from 1 December 2016.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INFECTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>74 TOBRAMYCIN (brand change)</td>
</tr>
<tr>
<td>Note – DBL Tobramycin inj 40 mg per ml, 2 ml vial to be delisted from 1 February 2017.</td>
</tr>
</tbody>
</table>
Changes to Section H Part II – effective 1 December 2016 (continued)

86 ENFUVIRIDE (delisting)
  ➞ Inj 108 mg vial x 60 ............................................................. 2,380.00 1 Fuzeon
  Note – Fuzeon inj 108 mg vial x 60 to be delisted from 1 February 2017.

94 PARITAPREVIR, RITONAVIR AND OMBITASVIR WITH DASABUVIR (website address amended)
  Note: Only for use in patients who have received supply of treatment via PHARMAC’s approved direct distribution supply.
  Application details for accessing treatment may be obtained from PHARMAC’s website
  Tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg
    (56), with dasabuvir tab 250 mg (56) .......................... 16,500.00 1 Viekira Pak

94 PARITAPREVIR, RITONAVIR AND OMBITASVIR WITH DASABUVIR AND RIBAVIRIN (website address amended)
  Note: Only for use in patients who have received supply of treatment via PHARMAC’s approved direct distribution supply.
  Application details for accessing treatment may be obtained from PHARMAC’s website
  Tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg
    (56) with dasabuvir tab 250 mg (56) and ribavirin
    tab 200 mg (168) .......................................................... 16,500.00 1 Viekira Pak-RBV

MUSCULOSKELETAL SYSTEM

103 ALLOPURINOL (new listing)
  Tab 100 mg .......................................................... 15.11 1,000 Allopurinol-Apotex
  Tab 300 mg .......................................................... 15.91 500 Allopurinol-Apotex

103 ALLOPURINOL (delisting)
  Tab 100 mg – 1% DV Mar-15 to 2017 ....................... 15.11 1,000 Apo-Allopurinol
  Tab 300 mg – 1% DV Mar-15 to 2017 ....................... 15.91 500 Apo-Allopurinol
  Note – Apo-Allopurinol tab 100 mg and 300 mg to be delisted from 1 June 2017.

NERVOUS SYSTEM

126 FLUPHENAZINE DECANOATE – Restricted: For continuation only (addition of restriction)
  Inj 12.5 mg per 0.5 ml ampoule .................................. 17.60 5 Modecate
  Inj 25 mg per ml, 1 ml ampoule .................................. 27.90 5 Modecate
  Inj 100 mg per ml, 1 ml ampoule .................................. 154.50 5 Modecate

127 ALPRAZOLAM – Restricted: For continuation only (addition of restriction)
  Tab 1 mg
  Tab 250 mcg
  Tab 500 mcg
Changes to Section H Part II – effective 1 December 2016 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

139 TEMOZOLOMIDE (brand change)

- Cap 5 mg – 1% DV Feb-17 to 2019 ............................................. 10.20 5 Orion Temozolomide
- Cap 20 mg – 1% DV Feb-17 to 2019 ............................................. 18.30 5 Orion Temozolomide
- Cap 100 mg – 1% DV Feb-17 to 2019 ......................................... 40.20 5 Orion Temozolomide
- Cap 250 mg – 1% DV Feb-17 to 2019 ......................................... 96.80 5 Orion Temozolomide

Note – Temaccord cap 5 mg, 20 mg, 100 mg and 250 mg to be delisted 1 February 2017.

147 ETANERCEPT (amended criteria shown only)

- Inj 25 mg vial ........................................................................... 799.96 4 Enbrel
- Inj 50 mg autoinjector ................................................................. 1,599.96 4 Enbrel
- Inj 50 mg syringe ....................................................................... 1,599.96 4 Enbrel

Restricted

Initiation — juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 4 months

Either:
1 Both:
1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
2 All of the following:
2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m2 weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
2.5 Both:
   2.5.1 Either:
      2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
   2.5.2 Physician’s global assessment indicating severe disease.

Initiation — rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months

Either:
1 Both:
1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

continued...
Changes to Section H Part II – effective 1 December 2016 (continued)

2 All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
2.5 Any of the following:
   2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
   2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
2.6 Either:
   2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
2.7 Either:
   2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation — ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months
Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
2 All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient’s ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an a regular exercise regimen for ankylosing spondylitis supervised by a physiotherapist; and
2.5 Either:
   2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober’s test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
continued...
Changes to Section H Part II – effective 1 December 2016 (continued)

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation — ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months

All of the following:

1. Following 12 weeks of etanercept treatment, following 12 weeks’ initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of by 50%, whichever is less; and

2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3. Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation — adult-onset Still’s disease
Rheumatologist
Re-assessment required after 6 months

Either:

1. Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2. All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.
Changes to Section H Part II – effective 1 December 2016 (continued)

153 ADALIMUMAB (amended criteria shown only)

- Inj 10 mg per 0.2 ml prefilled syringe .................. 1,599.96 2 Humira
- Inj 20 mg per 0.4 ml syringe .............................. 1,599.96 2 Humira
- Inj 40 mg per 0.8 ml pen .................................... 1,599.96 2 HumiraPen
- Inj 40 mg per 0.8 ml syringe ............................... 1,599.96 2 Humira

Restricted

Initiation — juvenile idiopathic arthritis
Rheumatologist or named specialist

*Re-assessment required after 6 4 months*

Either:

1. Either:
   1.1 Both:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
      1.1.2 Either:
         1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
         1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or

2. All of the following:
   2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
   2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:
   2.5.1 Either:
      2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
   2.5.2 Physician’s global assessment indicating severe disease.

Initiation — rheumatoid arthritis
Rheumatologist

*Re-assessment required after 6 months*

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or

2. All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (*either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive*) for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

*continued...*
Changes to Section H Part II – effective 1 December 2016 (continued)

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:

2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or

2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or

2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or

2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation — ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or

2 All of the following:

2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and

2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and

2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and

2.4 Patient’s ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis supervised by a physiotherapist; and

2.5 Either:

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober’s test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment. Average normal chest expansion corrected for age and gender:
Changes to Section H Part II – effective 1 December 2016 (continued)  
continued...

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation — ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Following 12 weeks of adalimumab treatment. Following 12 weeks’ initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI has improved by of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of by 50%, whichever is less; and

2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation — adult-onset Still’s disease

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.
Changes to Section H Part II – effective 1 December 2016 (continued)

167  RITUXIMAB (amended criteria shown only)

- Inj 10 mg per ml, 10 ml vial............................................. 1,075.50  2  Mabthera
- Inj 10 mg per ml, 50 ml vial............................................. 2,688.30  1  Mabthera

Restricted
Initiation — rheumatoid arthritis – TNF inhibitors contraindicated
Rheumatologist
Limited to 4 months treatment
All of the following:
1  Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
2  Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
3  Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
4  Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
5  Any of the following:
   5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
   5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
6  Either:
   6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
7  Either:
   7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
8  Either:
   8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
9  Maximum of two 1,000 mg infusions of rituximab given two weeks apart.
Changes to Section H Part II – effective 1 December 2016 (continued)

174 TOCILIZUMAB (amended criteria shown only)

- Injection 20 mg per ml, 4 ml vial
  - Price: $220.00
  - Brand: Actemra

- Injection 20 mg per ml, 10 ml vial
  - Price: $550.00
  - Brand: Actemra

- Injection 20 mg per ml, 20 ml vial
  - Price: $1,100.00
  - Brand: Actemra

Restricted

Initiation — Rheumatoid Arthritis

Re-assessment required after 6 months

Either:

1. All of the following:
   1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
   1.3 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
   1.4 Either:
      1.4.1 The patient has experienced intolerable side effects from rituximab; or
      1.4.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or

2. All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Tocilizumab is to be used as monotherapy; and
   2.3 Either:
      2.3.1 Treatment with methotrexate is contraindicated; or
      2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
   2.4 Either:
      2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or
      2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
   2.5 Either:
      2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
      2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
   2.6 Either:
      2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
      2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation — adult-onset Still’s disease

Reumatologist

Re-assessment required after 6 months

Either:

1. Both:
   1.1 Either:
Changes to Section H Part II – effective 1 December 2016 (continued)

1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still’s disease (AOSD); or
1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
1.2 Either:
1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
2 All of the following:
2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

RESPIRATORY SYSTEM AND ALLERGIES

183 CETIRIZINE HYDROCHLORIDE (↓ price and delayed delisting)
   Tab 10 mg ................................................................. 1.01 100 Zetop
   Note – Zetop tab 10 mg delisting delayed from 1 December 2016 until 1 March 2017.

183 CETIRIZINE HYDROCHLORIDE (HSS start date delayed)
   Tab 10 mg – 1% DV Dee-16 Mar-17 to 2019 ................................ 1.01 100 Zista

183 LORATADINE (brand change)
   Oral liq 1 mg per ml – 1% DV Feb-17 to 2019 ......................... 2.15 120 ml Lorfast
   Note – LoraPaed oral liq 1 mg per ml to be delisted from 1 February 2017.

SPECIAL FOODS

212 FAT-MODIFIED FEED (delisting)
   → Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat
   per 100 g, 400 g can
   e.g. Monogen
   Note – Monogen powder (old formulation) to be delisted from 1 February 2017. The new formulation remains listed.

Effective 22 November 2016

BLOOD AND BLOOD FORMING ORGANS

39 POTASSIUM CHLORIDE (HSS suspended)
   Tab long-acting 600 mg (8 mmol)
   – 1% DV Sep-15 to 2016 Feb-17 22 Nov 2016 ....................... 7.42 200 Span-K

39 SODIUM BICARBONATE (new Pharmacode listing)
   Cap 840 mg .............................................................. 8.52 100 Sodibic
   Note – Pharmacode 2513447 listed from 22 November 2016.
# Index
Pharmaceuticals and brands

<table>
<thead>
<tr>
<th>A</th>
<th>6, 13, 29</th>
<th>Actemra</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td>6, 25</td>
<td>Alloprim</td>
</tr>
<tr>
<td>Alglucosidase alfa</td>
<td>19</td>
<td>Alitraq</td>
</tr>
<tr>
<td>Allopurinol</td>
<td>9, 21</td>
<td>Alloprim-Apotex</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>4, 21</td>
<td>Antabuse</td>
</tr>
<tr>
<td>Apo-Allopurinol</td>
<td>9, 21</td>
<td>Apo-Paroxetine</td>
</tr>
<tr>
<td>Apo-Ondansetron</td>
<td>4</td>
<td>Apo-Terazosin</td>
</tr>
<tr>
<td>Arrow-Clopid</td>
<td>7</td>
<td>Arrow-Sumatriptan</td>
</tr>
<tr>
<td>Asacol</td>
<td>9</td>
<td>Avonex</td>
</tr>
<tr>
<td>B</td>
<td>7</td>
<td>Bupropion hydrochloride</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>7</td>
<td>Bupropion hydrochloride</td>
</tr>
<tr>
<td>Calsource</td>
<td>7</td>
<td>Ceftriaxone hydrochloride</td>
</tr>
<tr>
<td>Cetirizine hydrochloride</td>
<td>30</td>
<td>Clopidogrel</td>
</tr>
<tr>
<td>Clonidine</td>
<td>7</td>
<td>Clusuran</td>
</tr>
<tr>
<td>Codeine phosphate</td>
<td>6</td>
<td>Cytarabine</td>
</tr>
<tr>
<td>Cytoprev</td>
<td>6</td>
<td>Cytoprev</td>
</tr>
<tr>
<td>D</td>
<td>9</td>
<td>DDD</td>
</tr>
<tr>
<td>Derma-Act</td>
<td>20</td>
<td>Derma-Assist</td>
</tr>
<tr>
<td>Diazepam</td>
<td>10</td>
<td>Didanosine [DDI]</td>
</tr>
<tr>
<td>Disulfram</td>
<td>11</td>
<td>Disopropylfluorophosphate</td>
</tr>
<tr>
<td>Dopress</td>
<td>4</td>
<td>Dopress</td>
</tr>
<tr>
<td>Dosulepin (dothiepin) hydrochloride</td>
<td>4</td>
<td>Dosulepin (dothiepin) hydrochloride</td>
</tr>
<tr>
<td>Dothiepin</td>
<td>4</td>
<td>Dothiepin</td>
</tr>
<tr>
<td>E</td>
<td>19</td>
<td>Elaprase</td>
</tr>
<tr>
<td>Enbrel</td>
<td>11, 22</td>
<td>Enfuvirtide</td>
</tr>
<tr>
<td>Ensure (Chocolate)</td>
<td>6, 18</td>
<td>Ensure (Vanilla)</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>11</td>
<td>Estradiol</td>
</tr>
<tr>
<td>Esbriet</td>
<td>17</td>
<td>Estradiol</td>
</tr>
<tr>
<td>Etanercept</td>
<td>11, 22</td>
<td>Fat-modified feed</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>F</th>
<th>5</th>
<th>Filgrastim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluax</td>
<td>7</td>
<td>Fluoxetine</td>
</tr>
<tr>
<td>Fluphenazine decanoate</td>
<td>10, 21</td>
<td>Fuzen</td>
</tr>
<tr>
<td>G</td>
<td>7, 18</td>
<td>Gardasil</td>
</tr>
<tr>
<td>Gardasil</td>
<td>18</td>
<td>Gardasil 9</td>
</tr>
<tr>
<td>Glycine</td>
<td>11</td>
<td>Gentamicin sulphate</td>
</tr>
<tr>
<td>Glucose with potassium chloride and sodium chloride</td>
<td>4</td>
<td>Glucagon</td>
</tr>
<tr>
<td>Glycogen sodium chloride</td>
<td>4</td>
<td>Glycogen sodium chloride</td>
</tr>
<tr>
<td>Glycyl trinitrate</td>
<td>8</td>
<td>Glycyl trinitrate</td>
</tr>
<tr>
<td>H</td>
<td>15</td>
<td>Herceptin</td>
</tr>
<tr>
<td>HPV</td>
<td>7, 18</td>
<td>Humira</td>
</tr>
<tr>
<td>Human papillomavirus (6, 11, 16, 18) vaccine [HPV]</td>
<td>18</td>
<td>Human papillomavirus (6, 11, 16, 18) vaccine [HPV]</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>20</td>
<td>Hydrocortisone</td>
</tr>
<tr>
<td>I</td>
<td>19</td>
<td>Idrusulfase</td>
</tr>
<tr>
<td>Influenza vaccine</td>
<td>7</td>
<td>Influrvac</td>
</tr>
<tr>
<td>Interferon beta-1-alpha</td>
<td>5</td>
<td>Iodised oil</td>
</tr>
<tr>
<td>J</td>
<td>17</td>
<td>Iodised oil</td>
</tr>
<tr>
<td>L</td>
<td>20</td>
<td>Leuprolin acetate</td>
</tr>
<tr>
<td>Lidocaine-Clarithromycin</td>
<td>4</td>
<td>Lidocaine [lignocaine] hydrochloride</td>
</tr>
<tr>
<td>Lidocaine [lignocaine] hydrochloride</td>
<td>4</td>
<td>Lidocaine</td>
</tr>
<tr>
<td>Lignocaine</td>
<td>4</td>
<td>Lipiodol Ultra Fluid</td>
</tr>
<tr>
<td>Lipidol Ultra Fluid</td>
<td>17</td>
<td>Loradine</td>
</tr>
<tr>
<td>Loradine</td>
<td>30</td>
<td>Loradine</td>
</tr>
<tr>
<td>Lucrin Depot 6-month</td>
<td>20</td>
<td>Lucrin Depot 6-month</td>
</tr>
<tr>
<td>M</td>
<td>12, 28</td>
<td>Mabthera</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>4</td>
<td>Metformin hydrochloride</td>
</tr>
<tr>
<td>Metformin hydrochloride</td>
<td>5</td>
<td>Metformin Mylan</td>
</tr>
<tr>
<td>Metformin Mylan</td>
<td>5</td>
<td>Methyldopa</td>
</tr>
<tr>
<td>Methyldopa</td>
<td>4, 20</td>
<td>Methyldopa Mylan</td>
</tr>
<tr>
<td>Modecate</td>
<td>10, 21</td>
<td>Modecate</td>
</tr>
<tr>
<td>Monogen</td>
<td>30</td>
<td>Monogen</td>
</tr>
<tr>
<td>Myozyme</td>
<td>19</td>
<td>Myozyme</td>
</tr>
<tr>
<td>N</td>
<td>11</td>
<td>Naltraccord</td>
</tr>
<tr>
<td>Naltrexone hydrochloride</td>
<td>11</td>
<td>Naltrexone hydrochloride</td>
</tr>
<tr>
<td>Neosynephrine HCL</td>
<td>8</td>
<td>Neosynephrine HCL</td>
</tr>
</tbody>
</table>
Neulastim ............................................................... 7
Neupogen ............................................................... 5
Nitronal ................................................................. 8
O
Obinutuzumab ........................................................ 11
Oestradiol ............................................................... 8
Omnitrope ............................................................... 8
Ondansetron .......................................................... 4
Oral feed ............................................................... 6, 18
Orion Temozolomide ........................................... 22
P
Paediatric oral feed .................................................. 17
Paritaprevir, ritonavir and ombitasvir
with dasabuvir ................................................................. 21
Paritaprevir, ritonavir and ombitasvir
with dasabuvir and ribavirin ........................................... 21
Paroxetine ............................................................... 6
Pediasure (Vanilla) ................................................... 17
Pegfilgrastim ........................................................... 7
Peptide-based oral feed ........................................... 5
Perjeta ................................................................. 11
Pertuzumab ............................................................ 11
Phenylephrine hydrochloride ................................... 8
Pirfenidone ............................................................ 17
Potassium chloride .................................................. 30
Prednisonone ........................................................ 20
Prodopa ............................................................... 4, 20
R
Risedronate Sandoz ................................................. 9
Risedronate sodium ................................................. 9
Rituximab .............................................................. 12, 28
Rizamelt ................................................................. 4
Rizatriptan ............................................................. 4
S
Sodibic ................................................................. 30
Sodium bicarbonate ............................................... 30
Sodium chloride ..................................................... 5, 8
Sodium thiosulfate .................................................. 5
Somatropin ............................................................ 8
Span-K ................................................................. 30
Stesolid ............................................................... 10
Sumatriptan .......................................................... 6, 10
T
Tarceva ................................................................. 11
Temozolomide ........................................................ 22
Terazosin .............................................................. 5, 20
Tobramycin ........................................................... 20
Tobramycin Mylan .................................................. 20
Tocilizumab .......................................................... 6, 13, 29
Tramadol hydrochloride .......................................... 10
Trastuzumab ........................................................ 15
Trifluoperazine hydrochloride .................................. 10
V
Viekira Pak ............................................................ 21
Viekira Pak-RBV .................................................... 21
W
Water ................................................................. 8
Z
Zetop ................................................................. 30
Zista ................................................................. 30
Zyban ................................................................. 11